Details for New Drug Application (NDA): 022577
✉ Email this page to a colleague
NDA 022577 describes VIREAD, which is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. Additional details are available on the VIREAD profile page.
The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
Summary for 022577
| Tradename: | VIREAD |
| Applicant: | Gilead Sciences Inc |
| Ingredient: | tenofovir disoproxil fumarate |
| Patents: | 0 |
Pharmacology for NDA: 022577
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 022577
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577 | NDA | Gilead Sciences, Inc. | 61958-0403 | 61958-0403-1 | 1 BOTTLE, PLASTIC in 1 CARTON (61958-0403-1) / 60 g in 1 BOTTLE, PLASTIC |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | 40MG/SCOOPFUL | ||||
| Approval Date: | Jan 18, 2012 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
